Keywords
Urine detection
NMP22
OPN
BTA
Submitted : 2025-06-11
Accepted : 2025-06-26
Published : 2025-07-11
Abstract
Objective: To investigate the application value of urine nuclear matrix protein 22 (NMP22), osteopontin (OPN), and bladder tumor antigen (BTA) detection in the diagnostic and prognostic evaluation of bladder urothelial carcinoma. Methods: 100 patients with bladder urothelial carcinoma who visited our hospital from January 2020 to December 2022 were selected as the case group, and 100 healthy individuals who underwent physical examination during the same period were selected as the control group. The levels of NMP22, OPN, and BTA in the urine of the two groups were detected, and their diagnostic efficacy in bladder urothelial carcinoma was analyzed. The patients in the case group were followed up to observe the relationship between these markers and prognosis. Results: The levels of NMP22, OPN, and BTA in the urine of the case group were significantly higher than those of the control group (P < 0.05). The sensitivity, specificity, and accuracy of combined detection of NMP22, OPN, and BTA for diagnosing bladder urothelial carcinoma were higher than those of single marker detection (P < 0.05). Follow-up results showed that patients with high levels of NMP22, OPN, and BTA had a higher recurrence rate and shorter progression-free survival (P < 0.05). Conclusion: Combined detection of urine NMP22, OPN, and BTA has high diagnostic value for bladder urothelial carcinoma, and the levels of these markers are correlated with patient prognosis, which can be used for prognostic evaluation.
References
Siegel RL, Giaquinto AN, Jemal A, 2024, Cancer Statistics, 2024. CA Cancer J Clin, 74(1): 12–49.
Huang J, Zhang X (eds.), 2022, Guidelines for Diagnosis and Treatment of Urological and Andrological Diseases in China: 2022 Edition, Science Press, Beijing.
Chou R, Gore JL, Buckley D, et al., 2015, Urinary Biomarkers for Diagnosis of Bladder Cancer: A Systematic Review and Meta-Analysis. Ann Intern Med, 163(12): 922–931.
Wei R, Wong JPC, Kwok HF, 2017, Osteopontin—A Promising Biomarker for Cancer Therapy. J Cancer, 8(12): 2173–2183.
Babjuk M, Burger M, 2022, European Association of Urology Guidelines on Non-Muscle-Invasive Bladder Cancer. Eur Urol, 81(1): 75–94.
Shen ZJ, Hu MM, 2009, Research and Application Status of Urinary Tumor Markers for Bladder Cancer. Journal of Clinical Surgery, 2009(11): 3.
Liu C, Zhang CJ, Chen ZH, et al., 2024, Progress in Research and Application of Urinary Diagnostic Markers and Diagnostic Techniques for Bladder Cancer. Science China: Life Sciences, 2024(8).
Barboro P, Repaci E, D’Arrigo C, et al., 2012, The Role of Nuclear Matrix Proteins Binding to Matrix Attachment Regions (MARs) in Prostate Cancer Cell Differentiation. PLoS One, 7(7): e40617.
Cheng L, Zhao M, Wang LS, 2015, Application and Progress of Immunohistochemical Markers in the Diagnosis of Genitourinary System Tumors. Chinese Journal of Pathology, 44(5): 352–356.
Rangaswami H, Bulbule A, Kundu GC, 2006, Osteopontin: Role in Cell Signaling and Cancer Progression. Trends Cell Biol, 16(2): 79–87.
Ma YQ, 2019, Establishment of Multiple Detection Methods for Tumor Markers, dissertation, Changchun University of Science and Technology.
Shu QL, 2022, Detection of Tumor Markers Based on Chemiluminescent Aptamer Technology, dissertation, Nanchang University.
Lu RS, Yang Q, Lei PK, et al., 2021, Portable NMR Spectrometer for Rapid and Highly Sensitive Quantitative Detection of Tumor Markers, Proceedings of the Chinese Physical Society Spectroscopy Specialized Committee, 2.
Wang HL, Shi HB, 2024, Clinical Application Value of NMP22/Cr in the Diagnosis of Bladder Cancer in Primary Medical Units. Journal of Ningxia Medical University, 46(11): 1141–1145.
Yan XC, Zhang LD, 2016, Effects of Serum Vascular Endothelial Growth Factor and Osteopontin Levels on Lymph Node Metastasis in Bladder Cancer. Journal of Preventive Medicine of Chinese People’s Liberation Army, 34(05): 715–717.
Hou JQ, Guo ZH, Chen CL, et al., 1998, Clinical Significance of Bladder Tumor Antigen Detection in Bladder Cancer. Chinese Journal of Experimental Surgery, 15(03): 216–217.
Zhou BF, Liang PY, Ou SJ, et al., 2021, Clinical Application of Combined Detection of UBE2C and NMP22 in Urine for the Diagnosis of Bladder Cancer. Journal of International Urology and Nephrology, 41(4): 614–617.
Sun B, Zhang Z, 2015, Advances in Research of Osteopontin and Its Receptor CD44v in Tumor Invasion and Metastasis. Zhongguo Fei Ai Za Zhi, 18(11): 714–717.
Ling ST, Deng CL, Huang L, et al., 2021, The Value of Combined Detection of Bladder Tumor Antigen and Urinary Exfoliative Cytology in the Diagnosis of Bladder Tumors. Journal of International Urology and Nephrology, 41(2): 238–241.
Yang J, Suo J, Gao HF, 2020, Diagnostic Value of Combined Detection of Urinary Nuclear Matrix Protein 22 and Bladder Tumor Antigen for Bladder Cancer. Cancer Research and Clinic, 32(11): 772–775.